We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+5.61%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$253M
AUM Growth
+$63.7M
(+34%)
Cap. Flow
+$59.7M
Cap. Flow
% of AUM
23.62%
Top 10 Holdings %
Top 10 Hldgs %
44.38%
Holding
92
New
44
Increased
11
Reduced
15
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
|
+$13.9M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$12.1M |
| 3 |
Gilead Sciences
GILD
|
+$10.4M |
| 4 |
Takeda Pharmaceutical
TAK
|
+$8.8M |
| 5 |
Icon
ICLR
|
+$8.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$14.6M |
| 2 |
CELG
Celgene Corp
CELG
|
+$10.8M |
| 3 |
CVS Health
CVS
|
+$8.43M |
| 4 |
SHPG
Shire pic
SHPG
|
+$8.02M |
| 5 |
DaVita
DVA
|
+$7.24M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.31% |
| 2 | Technology | 10.37% |
| 3 | Industrials | 2.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$133B
| $13.9M | 5.49% |
291,281
+241,944
| +490% | +$12.1M |
|
|
IIN
2
DELISTED
IntriCon Corporation
IIN
| $13.9M | 5.48% |
552,457
+304,477
| +123% | +$7.73M |
|
|
3
Icon
ICLR
$12.6B
| $13.8M | 5.45% |
100,874
+59,742
| +145% | +$8.14M |
|
|
VCRA
4
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $12.4M | 4.89% |
+390,887
| New | +$13.9M |
|
5
Cigna
CI
$73.7B
| $10.8M | 4.26% |
66,997
-3,947
| -6% | -$721K |
|
6
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
| $10.5M | 4.14% |
+37,100
| New | +$10.1M |
|
|
7
Gilead Sciences
GILD
$162B
| $10.1M | 4% |
+155,793
| New | +$10.4M |
|
8
Zimmer Biomet
ZBH
$18.2B
| $9.87M | 3.9% |
79,605
-48,017
| -38% | -$5.46M |
|
|
9
Takeda Pharmaceutical
TAK
$54.6B
| $8.91M | 3.52% |
+437,436
| New | +$8.8M |
|
10
HCA Healthcare
HCA
$87.2B
| $7.83M | 3.1% |
+60,075
| New | +$8.07M |
|
|
WMGI
11
DELISTED
Wright Medical Group Inc
WMGI
| $7.78M | 3.08% |
247,417
-34,691
| -12% | -$1.05M |
|
|
RCM
12
DELISTED
R1 RCM Inc. Common Stock
RCM
| $7.26M | 2.87% |
750,376
-143,045
| -16% | -$1.29M |
|
13
AtriCure
ATRC
$1.92B
| $7.14M | 2.82% |
+266,577
| New | +$8.1M |
|
14
Cencora
COR
$60.6B
| $7.04M | 2.78% |
88,536
+80,196
| +962% | +$6.44M |
|
15
Labcorp
LH
$25B
| $6.86M | 2.71% |
+52,228
| New | +$6.43M |
|
|
AVDR
16
DELISTED
Avedro, Inc Common Stock
AVDR
| $5.42M | 2.14% |
+441,989
| New | +$5.53M |
|
17
Evolent Health
EVH
$348M
| $5.27M | 2.08% |
+418,728
| New | +$6.63M |
|
18
LivaNova
LIVN
$4.4B
| $4.12M | 1.63% |
+42,312
| New | +$3.95M |
|
19
iRhythm Holdings
IRTC
$3.85B
| $3.77M | 1.49% |
50,333
+32,315
| +179% | +$2.76M |
|
20
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
| $3.73M | 1.48% |
+40,700
| New | +$3.67M |
|
21
Tenet Healthcare
THC
$20.5B
| $3.51M | 1.39% |
+121,823
| New | +$3.01M |
|
22
Aclaris Therapeutics
ACRS
$726M
| $3.27M | 1.29% |
+545,729
| New | +$3.62M |
|
23
Medtronic
MDT
$109B
| $3.24M | 1.28% |
35,579
-57,248
| -62% | -$5.12M |
|
24
PUT
Invesco QQQ Trust
QQQ
$453B
| $2.98M | 1.18% |
+16,600
| New | +$2.82M |
|
25
Centene
CNC
$30.7B
| $2.92M | 1.15% |
+54,995
| New | +$3.34M |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Endurant Capital Management held 92 positions worth $253M, up 34% from $189M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Endurant Capital Management deployed $59.7M of net new capital in Q1 2019, opening 44 new positions and adding to 11 existing holdings. Its largest new stake was VOCERA COMMUNICATIONS, INC.: 390,887 shares worth $12.4M.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 91% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Allergan plc, an estimated $14.6M trimmed.
- Endurant Capital Management's largest Q1 2019 buy was VOCERA COMMUNICATIONS, INC.: 390,887 shares worth $12.4M.
- Endurant Capital Management added most to Bristol-Myers Squibb in Q1 2019, an estimated $12.1M increase.
- Endurant Capital Management's biggest Q1 2019 reduction was Allergan plc, cutting an estimated $14.6M.
- Endurant Capital Management fully exited Celgene Corp in Q1 2019, selling an estimated $10.8M.
- Endurant Capital Management's ten largest holdings make up 44% of its $253M portfolio in Q1 2019.
- Endurant Capital Management opened 44 new positions and closed 22 in Q1 2019.
- Endurant Capital Management's portfolio value rose 34% quarter-over-quarter to $253M.
Based on Endurant Capital Management's 13F filing for Q1 2019, filed 15 May 2019.